Exploring Breakthroughs and Challenges in NASH Management
Nonalcoholic Steatohepatitis (NASH) represents a critical advancement of Nonalcoholic Fatty Liver Disease, marked by inflammation and fat buildup similar to alcohol-induced liver damage. With the absence of FDA-approved medications until recently, lifestyle changes have been vital in managing NASH. The introduction of Rezdiffra offers new pathways in treatment, while ongoing research explores genetic and environmental […]
3 minute read